Overview

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Status:
Completed

Trial end date:
2017-10-19

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the feasibility of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate for adjuvant treatment of early stage breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Cyclophosphamide
Doxorubicin
Liposomal doxorubicin